Keywords: Summit Pharma, Bristol-Myers Squibb, Seglin technology, Mutiple therapeutic targets

Summit licenses Seglin technology to Bristol-Myers

Article | 12 September 2012

UK drug discovery firm Summit Pharmaceuticals (AIM: SUMM) has entered a technology license agreement with pharma major Bristol-Myers Squibb (NYSE: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Summit Pharmaceuticals

Go to company listing